Form 8-K - Current report:
SEC Accession No. 0001193125-25-068759
Filing Date
2025-03-31
Accepted
2025-03-31 16:13:17
Documents
13
Period of Report
2025-03-28
Items
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d848903d8k.htm   iXBRL 8-K 29373
  Complete submission text file 0001193125-25-068759.txt   149136

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA advm-20250328.xsd EX-101.SCH 2851
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE advm-20250328_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE advm-20250328_pre.xml EX-101.PRE 10813
16 EXTRACTED XBRL INSTANCE DOCUMENT d848903d8k_htm.xml XML 3516
Mailing Address 100 CARDINAL WAY REDWOOD CITY CA 94063
Business Address 100 CARDINAL WAY REDWOOD CITY CA 94063 (650) 649-1004
Adverum Biotechnologies, Inc. (Filer) CIK: 0001501756 (see all company filings)

EIN.: 205258327 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36579 | Film No.: 25793375
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)